The Joe Tippens protocol profoundly impacted cancer patient communities worldwide, triggering a global wave of interest in drug repositioning and unmonitored self-administration of veterinary antiparasitics.
1. Origin of the Protocol and Social Media Dissemination
The Case of Joe Tippens: In 2016, Joe Tippens, an Oklahoma businessman diagnosed with late-stage small-cell lung cancer and given a prognosis of 3 to 12 months, began taking fenbendazole (222 mg/day) alongside vitamin E supplements, CBD oil, and bioavailable curcumin based on a veterinarian’s advice while participating in a clinical trial for pembrolizumab.
Viral Reach: After scans showed a complete response, Tippens attributed his recovery to fenbendazole and documented his story online. He launched the blog Get Busy Living and created a closed Facebook group (My Cancer Story Rocks, reaching nearly 34,000 members). The blog reached readers across more than 60 countries and outlined self-administration dosages for various malignancies, including colorectal, lung, prostate, and brain cancers.
2. The “Fenbendazole Fever” in South Korea
Explosive Online Spread: The phenomenon experienced its most dramatic expansion in South Korea, where cancer has been the leading cause of death since 1983. In September 2019, a South Korean YouTube video featuring Tippens’ story amassed over 2.4 million views within 3 months.
Search Volume Dominance: At the peak of interest, South Korea accounted for 70.3% of all global Google search queries regarding fenbendazole as a cancer therapy.
Celebrity Endorsement and Supply Shortages: South Korean comedian Kim Chul-Min, diagnosed with Stage 4 lung cancer, publicly adopted the protocol and documented his experience online. This public endorsement led to widespread supply shortages in veterinary pharmacies across the country and prompted desperate patients to seek out “auto-prescriptions”. (Kim later stopped taking fenbendazole after 8 months due to lack of efficacy and severe side effects prior to his death).
3. Peer-to-Peer Networks and Informal Markets
Unregulated Patient Trade: Social network channels quickly evolved into peer-to-peer marketplaces where patients traded or sold veterinary dewormers directly to one another—bypassing healthcare regulations and medical supervision.
Interest in Other Benzimidazoles: Search activity expanded beyond fenbendazole to encompass other human and animal antiparasitics, including mebendazole, albendazole, flubendazole, niclosamide, and ivermectin.
4. Clinical Risks, Medical Warnings, and Trial Confounding
Documented Toxicity: Unmonitored self-administration resulted in clinical complications. Case reports documented instances of drug-induced liver injury (DILI), such as an 80-year-old lung cancer patient receiving pembrolizumab who developed severe liver enzyme spikes after taking oral fenbendazole for a month based on social media advice.
Regulatory Interventions: Major health authorities—including the Korean Medical Association, Korean Pharmaceutical Association, Korean Veterinary Association, and Ministry of Food and Drug Safety—issued formal public warnings against self-administering animal dewormers due to the total absence of human safety, pharmacokinetic, and clinical trial evidence.
Disruption of Formal Clinical Research: Oncologists noted that secret self-administration confounds formal clinical trials. When trial participants take unapproved compounds simultaneously, it becomes impossible to determine whether therapeutic benefits or toxic side effects stem from the trial drug or the dewormer, causing severe financial and research setbacks.
5. Drive for Controlled Clinical Evidence
Call for Interdisciplinary Evaluations: The global public surge highlighted the immense desperation of terminal cancer patients facing limited options. Medical researchers emphasized that reprimanding patients is ineffective and argued instead for interdisciplinary research teams (oncologists, veterinarians, and pharmacologists) to establish proper human dosing profiles and conduct rigorous, evidence-based clinical trials.
Jung, H., Lee, Y.-J., & Joo, H.-G. (2023). Differential cytotoxic effects of fenbendazole on mouse lymphoma EL-4 cells and spleen cells. Korean Journal of Veterinary Research, 63(1), Article e2. https://doi.org/10.14405/kjvr.20220040
Li, W., Jaga, S., Shah, S., & Cearras, M. (2025). Cancer’s metabolic hijack: The under-recognized hematologic emergency related to the Warburg effect. Cureus, 17(1), Article e77869. https://doi.org/10.7759/cureus.77869
Park, D., Lee, J.-H., & Yoon, S.-P. (2022). Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells. Korean Journal of Physiology & Pharmacology, 26(5), 377–387. https://doi.org/10.4196/kjpp.2022.26.5.377
Sultana, T., Jan, U., Lee, H., Lee, H., & Lee, J. I. (2022). Exceptional repositioning of dog dewormer: Fenbendazole fever. Current Issues in Molecular Biology, 44(10), 4977–4986. https://doi.org/10.3390/cimb44100338
Maybe you should talk to Joe on the success stories instead. Korea has always had a negative view.
Very true, good idea.